MarketBeat
26 May 2026, 23:04 UTC · 2h ago
Source · https://www.marketbeat.com/instant-alerts/ideaya-biosciences-spotlights-darovasertib-win-fda-review-path-at-oncology-summit-2026-05-26/
Read source
Story key points
5 claims · impact-rated
IDEAYA's Phase II/III study of darovasertib plus crizotinib in HLA-A*02-negative metastatic uveal melanoma met its primary endpoint with a PFS hazard ratio of 0.42 (p < 0.0001). — Meeting a primary endpoint for a registrational study with high statistical significance is a major catalyst for potential FDA accelerated approval and revenue generation.
+0.90The FDA has granted Real-Time Oncology Review (RTOR) for the darovasertib plus crizotinib program, with the first NDA module already submitted. — RTOR streamlines the submission process and can significantly shorten the time to market, accelerating potential commercialization.
+0.60IDEAYA reported overall survival of just over 21 months for frontline patients, compared to 12.5 months in a referenced ipilimumab/nivolumab study. — Strong survival data supports the long-term value proposition and the likelihood of full approval following accelerated approval.
+0.50Search tags
The company expects two data sets for its DLL3-targeted ADC (IDE849) later this year, including 12-month landmark overall survival data. — Provides a secondary near-term catalyst and validates the company's expansion into ADCs beyond its primary oncology focus.
+0.40IDEAYA is initiating a large-scale (450 patient) adjuvant study for darovasertib to move the therapy into earlier-stage disease. — Expanding into earlier-stage disease increases the total addressable market (TAM), though the readout is far in the future (3+ years).
+0.30Impact vectors
6 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Ticker attribution
Model heads
Positive clinical results for darovasertib in uveal melanoma, including meeting a primary endpoint for accelerated approval and a potential multi-billion-dollar blockbuster opportunity.
Mentioned as a partner expanding the IDE849 ADC program, suggesting collaborative progress in the small cell lung cancer pipeline.
